ArticleBMC gastroenterology2025
Initial development and validation of a disease-specific resilience measure for inflammatory bowel disease: the RISE-IBD instrument.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInflammatory bowel diseases (IBDs) have a substantial effect on the well-being and quality of life of patients. While resilience may help alleviate psychological and physical burdens in individuals with IBD, there is no disease-specific measure that currently exists to accurately quantify this construct in the context of IBD. This study aimed to psychometrically validate the new Resilience Scale for IBD (RISE-IBD).
methodsA preliminary scale was developed including 17 items generated from a qualitative study that centered on patient focus group discussions, conversations with IBD healthcare providers, and evaluation of two validated resilience measures. In this cross-sectional study, the scale's reliability, validity, and consistency were assessed in a sample of 91 patients with IBD.
resultsThe 17-item RISE-IBD was reduced to a 14-item measure. The revised RISE-IBD, comprising four resilience domains (Disease Acceptance, Self-Reliance, Flexibility, Persistence), demonstrated strong internal consistency (Cronbach's α = 0.82) and excellent re-test reliability (r = 0.91). The scale exhibited significantly positive correlations with the Connor-Davidson Resilience Scale (r = 0.74) and Brief Resilience Scale (r = 0.59), as well as with a disease-specific quality of life scale, the IBD Questionnaire (τ = 0.33). It also showed significantly negative associations with psychological distress measured by the Brief Symptom Inventory (τ = -0.36) and IBD-related disability assessed by the IBD Disability Index (τ = -0.30).
conclusionsThe RISE-IBD demonstrates its strong potential as a psychometrically reliable tool for assessing resilience in patients with IBD. By evaluating resilience across multiple domains, healthcare providers can gain a thorough understanding of patients' coping mechanisms and tailor interventions accordingly. Future research should focus on further strengthening the scale's psychometric properties by validating its use across diverse gastrointestinal patient populations and exploring the relationship between resilience and key IBD outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.